Free Trial
NASDAQ:BMRA

Biomerica (BMRA) Stock Price, News & Analysis

Biomerica logo
$0.37
0.00 (0.00%)
(As of 11/1/2024 ET)

About Biomerica Stock (NASDAQ:BMRA)

Key Stats

Today's Range
$0.35
$0.38
50-Day Range
$0.28
$0.49
52-Week Range
$0.24
$2.13
Volume
200,489 shs
Average Volume
235,109 shs
Market Capitalization
$6.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Biomerica Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
18th Percentile Overall Score

BMRA MarketRank™: 

Biomerica scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biomerica is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biomerica is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biomerica has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Biomerica's valuation and earnings.
  • Percentage of Shares Shorted

    2.22% of the outstanding shares of Biomerica have been sold short.
  • Short Interest Ratio / Days to Cover

    Biomerica has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biomerica has recently decreased by 14.87%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Biomerica does not currently pay a dividend.

  • Dividend Growth

    Biomerica does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.22% of the outstanding shares of Biomerica have been sold short.
  • Short Interest Ratio / Days to Cover

    Biomerica has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biomerica has recently decreased by 14.87%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Biomerica has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Biomerica this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added Biomerica to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biomerica insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 22.28% of the stock of Biomerica is held by institutions.

  • Read more about Biomerica's insider trading history.
Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

BMRA Stock News Headlines

Biomerica Gains on IBS Announcement
True paradigm shift
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Biomerica Reports Fiscal 2024 Year End Results
See More Headlines

BMRA Stock Analysis - Frequently Asked Questions

Biomerica's stock was trading at $1.25 at the start of the year. Since then, BMRA stock has decreased by 70.2% and is now trading at $0.3720.
View the best growth stocks for 2024 here
.

Biomerica, Inc. (NASDAQ:BMRA) announced its quarterly earnings data on Tuesday, October, 15th. The company reported ($0.08) EPS for the quarter. The business had revenue of $1.81 million for the quarter. Biomerica had a negative trailing twelve-month return on equity of 84.62% and a negative net margin of 111.89%.

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biomerica investors own include Pfizer (PFE), Gilead Sciences (GILD), AT&T (T), NIO (NIO), Exxon Mobil (XOM), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Company Calendar

Last Earnings
10/15/2024
Today
11/02/2024
Next Earnings (Estimated)
1/21/2025
Fiscal Year End
5/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BMRA
Employees
60
Year Founded
1971

Profitability

Net Income
$-5,980,000.00
Net Margins
-111.89%
Pretax Margin
-111.48%

Debt

Sales & Book Value

Annual Sales
$5.41 million
Book Value
$0.32 per share

Miscellaneous

Free Float
14,299,000
Market Cap
$6.26 million
Optionable
Optionable
Beta
-1.11

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:BMRA) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners